Video

Dr. Sehn Discusses the GAUSS Obinutuzumab Trial

Dr. Laurie Sehn, from the British Columbia Cancer Agency, Discusses the GAUSS Obinutuzumab Trial

Laurie H. Sehn, MD, MPH, clinical associate professor in the division of medical oncology at the University of British Columbia and the British Columbia Cancer Agency, discusses the phase II randomized GAUSS trial that demonstrated a trend towards a higher objective response rate to obinutuzumab (GA101) compared with rituximab (Rituxan), for patients with indolent non-Hodgkin lymphoma.

Sehn describes the GAUSS trial as the first head-to-head comparison of a novel CD20 monoclonal antibody and rituximab.

Patients in the trial were randomized 1:1 to receive either obinutuzumab or rituximab in 4 weekly induction therapies. Response was assessed following the induction treatment at 24 and 48 days. Patients that did not demonstrate any evidence of disease progression received a maintenance therapy of obinutuzumab or rituximab every 2 months for 2 years.

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD